Dopamine Receptors in Human Adipocytes: Expression and Functions
Open Access
- 26 September 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e25537
Abstract
Dopamine (DA) binds to five receptors (DAR), classified by their ability to increase (D1R-like) or decrease (D2R-like) cAMP. In humans, most DA circulates as dopamine sulfate (DA-S), which can be de-conjugated to bioactive DA by arylsulfatase A (ARSA). The objective was to examine expression of DAR and ARSA in human adipose tissue and determine whether DA regulates prolactin (PRL) and adipokine expression and release. DAR were analyzed by RT-PCR and Western blotting in explants, primary adipocytes and two human adipocyte cell lines, LS14 and SW872. ARSA expression and activity were determined by qPCR and enzymatic assay. PRL expression and release were determined by luciferase reporter and Nb2 bioassay. Analysis of cAMP, cGMP, leptin, adiponectin and interleukin 6 (IL-6) was done by ELISA. Activation of MAPK and PI3 kinase/Akt was determined by Western blotting. DAR are variably expressed at the mRNA and protein levels in adipose tissue and adipocytes during adipogenesis. ARSA activity in adipocyte increases after differentiation. DA at nM concentrations suppresses cAMP, stimulates cGMP, and activates MAPK in adipocytes. Acting via D2R-like receptors, DA and DA-S inhibit PRL gene expression and release. Acting via D1R/D5R receptors, DA suppresses leptin and stimulates adiponectin and IL-6 release. This is the first report that human adipocytes express functional DAR and ARSA, suggesting a regulatory role for peripheral DA in adipose functions. We speculate that the propensity of some DAR-activating antipsychotics to increase weight and alter metabolic homeostasis is due, in part, to their direct action on adipose tissue.Keywords
This publication has 56 references indexed in Scilit:
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-AnalysisNeuropsychopharmacology, 2010
- Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategiesTrends in Pharmacological Sciences, 2009
- Saposin B-dependent Reconstitution of Arylsulfatase A Activity in Vitro and in Cell Culture Models of Metachromatic LeukodystrophyJournal of Biological Chemistry, 2009
- Short‐term β‐adrenergic regulation of leptin, adiponectin and interleukin‐6 secretion in vivo in lean and obese subjectsDiabetes, Obesity and Metabolism, 2008
- Prolactin Release by Adipose Explants, Primary Adipocytes, and LS14 AdipocytesThe Journal of Clinical Endocrinology & Metabolism, 2008
- Insulin Stimulates Interleukin-6 Expression and Release in LS14 Human Adipocytes through Multiple Signaling PathwaysEndocrinology, 2008
- Insulin regulates leptin secretion from 3T3–L1 adipocytes by a PI 3 kinase independent mechanismExperimental Cell Research, 2008
- Adipocyte prolactin: regulation of release and putative functionsDiabetes, Obesity and Metabolism, 2006
- Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissueJournal of Endocrinology, 2006
- Contribution of arylsulfatase A mutations located on the same allele to enzyme activity reduction and metachromatic leukodystrophy severityHuman Genetics, 2002